Cover Image
市場調查報告書

SIGA Technologies, Inc.:產品平台分析

SIGA Technologies, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224727
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
SIGA Technologies, Inc.:產品平台分析 SIGA Technologies, Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 33 Pages
簡介

SIGA Technologies, Inc.是開發天花、拉薩熱、伊波拉病毒、登革熱等殺傷力強的病原體解決方案的製藥企業。

本報告提供SIGA Technologies, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

SIGA Technologies, Inc.的基本資料

SIGA Technologies, Inc.概要

  • 主要資訊
  • 企業資料

SIGA Technologies, Inc.:R&D概要

  • 主要的治療範圍

SIGA Technologies, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

SIGA Technologies, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
  • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

SIGA Technologies, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

SIGA Technologies, Inc.:藥物簡介

  • tecovirimat
  • ST-148
  • ST-193
  • ST-294
  • ST-610
  • Bunya病毒小分子
  • 流感病毒小分子
  • 天花疫苗
  • ST-161
  • ST-669

SIGA Technologies, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

SIGA Technologies, Inc.:最近的開發平台趨勢

SIGA Technologies, Inc.:暫停中的計劃

SIGA Technologies, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07613CDB

Summary

Global Markets Direct's, 'SIGA Technologies, Inc. - Product Pipeline Review - 2015', provides an overview of the SIGA Technologies, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SIGA Technologies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SIGA Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SIGA Technologies, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SIGA Technologies, Inc.'s pipeline products

Reasons to buy

  • Evaluate SIGA Technologies, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SIGA Technologies, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SIGA Technologies, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SIGA Technologies, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SIGA Technologies, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SIGA Technologies, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SIGA Technologies, Inc. Snapshot
    • SIGA Technologies, Inc. Overview
    • Key Information
    • Key Facts
  • SIGA Technologies, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • SIGA Technologies, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • SIGA Technologies, Inc. - Pipeline Products Glance
    • SIGA Technologies, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • SIGA Technologies, Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • SIGA Technologies, Inc. - Drug Profiles
    • tecovirimat
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-148
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-324
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-610
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-161
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ST-669
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SIGA Technologies, Inc. - Pipeline Analysis
    • SIGA Technologies, Inc. - Pipeline Products by Target
    • SIGA Technologies, Inc. - Pipeline Products by Route of Administration
    • SIGA Technologies, Inc. - Pipeline Products by Molecule Type
    • SIGA Technologies, Inc. - Pipeline Products by Mechanism of Action
  • SIGA Technologies, Inc. - Recent Pipeline Updates
  • SIGA Technologies, Inc. - Dormant Projects
  • SIGA Technologies, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SIGA Technologies, Inc., Key Information
  • SIGA Technologies, Inc., Key Facts
  • SIGA Technologies, Inc. - Pipeline by Indication, 2015
  • SIGA Technologies, Inc. - Pipeline by Stage of Development, 2015
  • SIGA Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • SIGA Technologies, Inc. - Phase III, 2015
  • SIGA Technologies, Inc. - IND/CTA Filed, 2015
  • SIGA Technologies, Inc. - Preclinical, 2015
  • SIGA Technologies, Inc. - Discovery, 2015
  • SIGA Technologies, Inc. - Pipeline by Target, 2015
  • SIGA Technologies, Inc. - Pipeline by Route of Administration, 2015
  • SIGA Technologies, Inc. - Pipeline by Molecule Type, 2015
  • SIGA Technologies, Inc. - Pipeline Products by Mechanism of Action, 2015
  • SIGA Technologies, Inc. - Recent Pipeline Updates, 2015
  • SIGA Technologies, Inc. - Dormant Developmental Projects,2015
  • SIGA Technologies, Inc., Other Locations

List of Figures

  • SIGA Technologies, Inc. - Pipeline by Top 10 Indication, 2015
  • SIGA Technologies, Inc. - Pipeline by Stage of Development, 2015
  • SIGA Technologies, Inc. - Monotherapy Products in Pipeline, 2015
  • SIGA Technologies, Inc. - Pipeline by Top 10 Target, 2015
  • SIGA Technologies, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • SIGA Technologies, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • SIGA Technologies, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top